NEW DATA: Driving Durable Relief in Atopic Dermatitis with Nektar’s REZPEG IL-2 Platform
- Showcasing the unique mechanism of Nektar’s REZPEG IL-2 platform and why it is effective in modulating immune balance
- Highlighting long-term maintenance data from the REZOLVE-AD study to demonstrate sustained efficacy and patient benefit
- Exploring how REZPEG can redefine therapeutic expectations for chronic atopic dermatitis management